5-Lipoxygenase-activating protein inhibitors: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl] -5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)

Journal of Medicinal Chemistry

Volumn 52, Issue 19, 2009, Pages 5803-5815

  Hutchinson, John H ^a   Li, Yiwei ^a   Arruda, Jeannie M ^a   Baccei, Christopher ^a   Bain, Gretchen ^a   Chapman, Charles ^a   Correa, Lucia ^a   Darlington, Janice ^a   King, Christopher D ^a   Lee, Catherine ^a   Lorrain, Dan ^a   Prodanovich, Pat ^a   Rong, Haojing ^a   Santini, Angelina ^a   Stock, Nicholas ^a   Prasit, Peppi ^a   Evans, Jilly F ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (THIAZOL 2 YL)BENZYL 3 [3 (3,3 DIMETHYLBUT 1 YL) 5 (PYRIDINE 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 1 (THIAZOL 2 YL)BENZYL 3 [3 (CYCLOBUTYLCARBONYL) 5 (PYRIDINE 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 1 (THIAZOL 2 YL)BENZYL 3 [3 (CYCLOBUTYLMETHYL) 5 (PYRIDINE 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 1 (THIAZOL 2 YL)BENZYL 3 [3 TERT BUTYLSULFANYL 5 (PYRIDINE 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 1 (THIAZOL 2 YL)BENZYL 3 [5 (PYRIDINE 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLSULFANYL 1 [4 (6 METHOXYPYRIDIN 3 YL) BENZYL] 5 (PYRIDIN 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLSULOXIDE 1 [4 (6 METHOXYPYRIDIN 3 YL) BENZYL] 5 (PYRIDIN 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYLPROPIONIC ACID; AM 103; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYTOCHROME P450 3A4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EXPERIMENTAL DOG; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASTHMA; CARRIER PROTEINS; DOGS; DRUG TOXICITY; HETEROCYCLIC COMPOUNDS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LEUKOTRIENE B4; MEMBRANE PROTEINS; MICE; PROPIONIC ACIDS; PROTEIN BINDING; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349648499     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900945d     Document Type: Article

References (52)

1. Samuelsson, B. The discovery of the leukotrienes. Am. J. Respir. Crit. Care Med. 2000, 161, S2-S6.
2. Dixon, R. A. F.; Diehl, R. E.; Opas, E.; Rands, E.; Vickers, P. J.; Evans, J. E.; Gillard, J. W.; Miller, D. K. Nature 1990, 343, 282-284.
3. (b) Evans, J. F.; Ferguson, A. D.; Mosley, R. T.; Hutchinson, J. H. What's all the FLAP about?: 5-Lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 2008, 29, 72-78.
4. Figueroa, D. J.; Breyer, R. M.; Defoe, S. K.; Kargman, S.; Daugherty, B. L.; Waldburger, K.; Liu, Q.; Clements, M.; Zeng, Z.; O'Neill, G. P.; Jones, T. R.; Lynch, K. R.; Austin, C. P.; Evans, J. F. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am. J. Respir. Crit. Care Med. 2001, 163, 226-233.
5. Heise, C. E.; O'Dowd, B. F.; Figueroa, D. J.; Sawyer, N.; Nguyen, T.; Im, D.-S.; Stocco, R.; Bellefeuille, J. N.; Abramovitz, M.; Cheng, R.; Williams, D. L.; Zeng, Z.; Liu, Q.; Ma, L.; Clements, M. K.; Coulombe, N.; Liu, Y.; Austin, C. P.; George, S. R.; O'Neill, G. P.; Metters, K. M.; Lynch, K. R.; Evans, J. F. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 2000, 275, 30531-30536. (Pubitemid 30751375)
6. Ciana, P.; Fumagalli, M.; Trincavelli, M. L.; Verderio, C.; Rosa, P.; Lecca, D.; Ferrario, S.; Parravicini, C.; Capra, V.; Gelosa, P.; Guerrini, U.; Belcredito, S.; Cimino, M.; Sironi, L.; Tremoli, E.; Rovati, G. E.; Martini, C.; Abbracchio, M. P. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006, 25, 4615-4627.
7. Nonaka, Y.; Hiramoto, T.; Fujita, N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem. Biophys. Res. Commun. 2005, 337, 281-288. (Pubitemid 41393791)
8. Maekawa, A.; Kanaoka, Y.; Xing, X.; Austen, K. F. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 16695-16700.
9. Drazen, J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am. J. Respir. Crit. Care Med. 1998, 157, S233-S237. (Pubitemid 28304149)
10. Young, R. N. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Chem. 1999, 34, 671-685.
11. (a) Diamant, Z.; Timmers, M. C.; van der Veen, H.; Friedman, B. S.; De Smet, M.; Depre, M.; Hilliard, D.; Bel, E. H.; Sterk, P. J. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allegen-induced airway response in asthmatic subjects in vivo. J. Allergy Clin. Immunol. 1995, 95, 42-51.
12. (b) Chapman, K. R.; Friedman, B. S.; Shingo, S.; Heyse, J.; Reiss, T.; Spector, R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am. J. Respir. Crit. Care Med. 1994, 149, A215.
13. Brideau, C.; Chan, C.; Charleson, S.; Denis, D.; Evans, J. F.; Ford- Hutchinson, A. W.; Hutchinson, J. H.; Jones, T. R.; Léger, S.; Mancini, J. A.; McFarlane, C. S.; Pickett, C.; Piechuta, H.; Prasit, P.; Riendeau, D.; Rouzer, C. A.; Tagari, P.; Vickers, P. J.; Young, R. N.; Abraham, W. M. Pharmacology of MK-0591 (3-[1-(4- chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2- ylmethoxy)-indol-2-yl]- 2,2-dimethylpropanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 1992, 70, 799-807.
14. Helgadottir, A.; Manolescu, A.; Thorleifsson, G.; Gretarsdottir, S.; Jonsdottir, H.; Thorsteinsdottir, U.; Samani, N.; Gudmundsson, G.; Grant, S. F. A.; Thorgeirsson, G.; Sveinbjornsdottir, S.; Valdimarsson, E. M.; Matthiasson, S.; Johannsson, H.; Gudmundsdottir, O.; Gurney, M. E.; Sainz, J.; Thorhallsdottir, M.; Andresdottir, M.; Frigge, M. L.; Topol, E. J.; Kong, A.; Gudnason, V.; Hakonarson, H.; Gulcher, J. R.; Stefansson, K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 2004, 36, 233-239. (Pubitemid 38282747)
15. Helgadottir, A.; Manolescu, A.; Helgason, A.; Thorleifsson, G.; Thorsteinsdottir, U.; Gudbjartsson, D. F.; Gretarsdottir, S.; Magnusson, K. P.; Gudmundsson, G.; Hicks, A.; Jonsson, T.; Grant, S. F. A.; Sainz, J.; O'Brien, S. J.; Sveinbjornsdottir, S.; Valdimarsson, E. M.; Matthiasson, S. E.; Levey, A. I.; Abramson, J. L.; Reilly, M. P.; Vaccarino, V.; Wolfe, M. L.; Gudnason, V.; Quyyumi, A. A.; Topol, E. J.; Rader, D. J.; Thorgeirsson, G.; Gulcher, J. R.; Hakonarson, H.; Kong, A.; Stefansson, K. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. 2005, 38, 68-74. (Pubitemid 43011884)
16. (a) Kajimoto, K.; Shioji, K.; Ishida, C.; Iwanaga, Y.; Kokubo, Y.; Tomoike, H.; Miyazaki, S.-i.; Nonogi, H.; Goto, Y.; Iwai, N. Validation of the association between the gene encoding 5-lipoxygenase- activating protein and myocardial infarction in a Japanese population. Circ. J. 2005, 69, 1029-1034.
17. (b) Girelli, D.; Martinelli, N.; Trabetti, E.; Olivieri, O.; Cavallari, U.; Malerba, G.; Busti, F.; Friso, S.; Pizzolo, F.; Franco Pignatti, P.; Corrocher, R. ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. Eur. J. Hum. Genet. 2007, 15, 959-966. (Pubitemid 47308472)
18. (c) Kaushal, R.; Pal, P.; Alwell, K.; Haverbusch, M.; Flaherty, M.; Moomaw, C.; Sekar, P.; Kissela, B.; Kleindorfer, D.; Chakraborty, R.; Broderick, J.; Deka, R.; Woo, D. Association of ALOX5AP with ischemic stroke: a population- based case-control study. Hum. Genet. 2007, 121, 601-607. (Pubitemid 46706071)
19. (d) Lohmussaar, E.; Gschwendtner, A.; Mueller, J. C.; Org, T.; Wichmann, E.; Hamann, G.; Meitinger, T.; Dichgans, M. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 2005, 36, 731-736. (Pubitemid 40490615)
20. (a) Fruchtmann, R.; Mohrs, K.-H.; Hatzelmann, A.; Raddatz, S.; Fugmann, B.; Junge, B.; Horstmann, H.; Muller-Peddinghaus, R. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993, 38, 188-195. (Pubitemid 23232265)
21. (b) Rossoni, G.; Sala, A.; Berti, F.; Testa, T.; Buccellati, C.; Molta, C.; Muller-Peddinghaus, R.; Maclouf, J.; Folco, G. C. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 1996, 276, 335-341.
22. Mehrabian, M.; Allayee, H.; Wong, J.; Shih, W.; Wang, X.-P.; Shaposhnik, Z.; Funk, C. D.; Lusis, A. J. Identification of 5- lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. 2002, 91, 120-126. (Pubitemid 34827222)
23. Zhao, L.; Moos, M. P.; Grabner, R.; Pédrono, F.; Fan, J.; Kaiser, B.; John, N.; Schmidt, S.; Spanbroek, R.; Lotzer, K.; Huang, L.; Cui, J.; Rader, D. J.; Evans, J. F.; Habenicht, A. J.; Funk, C. D. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nature Med. 2004, 10, 966-973. (Pubitemid 39273738)
24. (a) Rouzer, C. A.; Ford-Hutchinson, A. W.; Morton, H. E.; Gillard, J. W. MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5- lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem. 1990, 265, 1436-1442. (Pubitemid 20048962)
25. (b) Jawien, J.; Gajda, M.; Rudling, M.; Mateuszuk, L.; Olszanecki, R.; Guzik, T. J.; Cichocki, T.; Chlopicki, S.; Korbut, R. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 2006, 36, 141-146. (Pubitemid 43341263)
26. (a) Spanbroek, R.; Grabner, R.; Lotzer, K.; Hildner, M.; Urbach, A.; Ruhling, K.; Moos, M. P.; Kaiser, B.; Cohnert, T. U.; Wahlers, T.; Zieske, A.; Plenz, G.; Robenek, H.; Salbach, P.; Kuhn, H.; Radmark, O.; Samuelsson, B.; Habenicht, A. J. R. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad. Sci. U.S.A. 2002, 100, 1238-1243.
27. (b) Cipollone, F.; Mezzetti, A.; Fazia, M. L.; Cuccurullo, C.; Iezzi, A.; Ucchino, S.; Spigonardo, F.; Bucci, M.; Cuccurullo, F.; Prescott, S. M.; Stafforini, D. M. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler., Thromb., Vasc. Biol. 2005, 25, 1665-1670.
28. (c) Qiu, H.; Gabrielsen, A.; Agardh, H. E.; Wan, M.; Wetterholm, A.; Wong, C.-H.; Hedin, U.; Swedenborg, J.; Hansson, G. K.; Samuelsson, B.; Paulsson-Berne, G.; Haeggstrom, J. Z. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8161-8166.
29. (d) De Caterina, R.; Mazzone, A.; Giannessi, D.; Sicari, R.; Pelosi, W.; Lazzerini, G.; Azzara, A.; Forder, R.; Carey, F.; Caruso, D.; Galli, G.; Mosca, F. Leukotriene B4 in human atherosclerotic plaques. Biomed. Biochim. Acta. 1988, 47, S182-S185.
30. Hakonarson, H.; Thorvaldsson, S.; Helgadottir, A.; Gudbjartsson, D.; Zink, F.; Andresdottir, M.; Manolescu, A.; Arnar, D. O.; Andersen, K.; Sigurdsson, A.; Thorgeirsson, G.; Jonsson, A.; Agnarsson, U.; Bjornsdottir, H.; Gottskalksson, G.; Einarsson, A.; Gudmundsdottir, H.; Adalsteinsdottir, A. E.; Gudmundsson, K.; Kristjansson, K.; Hardarson, T.; Kristinsson, A.; Topol, E. J.; Gulcher, J.; Kong, A.; Gurney, M.; Thorgeirsson, G.; Stefansson, K. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. J.A.M.A. 2005, 293, 2277-2279. (Pubitemid 40629191)
31. (a) Brooks, C. D. W.; Stewart, A. O.; Basha, A.; Bhatia, P.; Ratajczyk, J. D.; Martin, J. G.; Craig, R. A.; Kolasa, T.; Bouska, J. B.; Lanni, C.; Harris, R. R.; Malo, P. E.; Carter, G. W.; Bell, R. L. (R)-(+)-N-[3-[5-[(4- fluorophenyl)methyl]-2-thienyl]-1-methyl-2- propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J. Med. Chem. 1995, 38, 4788-14755
32. (b) Tardiff, J.-C.; L'Allier, P. L.; Ibrahim, R.; Gregoire, J. C.; Hegedus, A.; Franc, J.; Blue, J.; Cooper, M.; Olukotun, A.; Taub, R. Three month of treatment with 5-lipoxygenase inhibitor VIA-2291 in patients with recent acute coronary syndrome. Circulation 2008, 118, 1260.
33. (c) Brotz, T. M.; De Blasis, G.; Carbonari, L.; Perry, M. S.; Chiang, E.; Hansson-Shea, A.; Cooper, M.; Olukotun, A.; Cipollone, F.; Taub, R. Three months of treatment with 5-lipoxygenase inhibitor VIA-2291 in patients scheduled for elective carotid endarterectomy surgery. Circulation 2008, 118, 1261.
34. Gillard, J. W., Morton, H. E., Fortin, R., Guindon, Y. U.S. Patent 5, 081, 138, Jan 14, 1992.
35. Brooks, D. W., Woods, K. W., Rodriques, K. E. U.S. Patent 5, 288, 743, Feb. 22, 1994.
36. Prasit, P., Fortin, R., Hutchinson, J. H., Belley, M. L., Leger, S., Frenette, R., Gillard, J. U.S. Patent 5, 272, 145, Dec 21, 1993.
37. Charleson, S.; Prasit, P.; Leger, S.; Gillard, J. W.; Vickers, P. J.; Mancini, J. A.; Charleson, P.; Guay, J.; Ford-Hutchinson, A. W.; Evans, J. F. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition. Mol. Pharmacol. 1992, 41, 873-879.
38. Uematsu, T.; Kananaru, M.; Kosuge, K.; Hara, K.; Uchiyama, N.; Takenaga, N.; Tanaka, W.; Friedman, B. S.; Nakashima, M. Pharmacokinetics and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers. Br. J. Clin. Pharmacol. 1995, 40, 59-66.
39. Down, B., Hutchinson, J. H. U.S. patent 5, 254, 567, Oct 19, 1993.
40. (a) Shenton, J. M.; Teranishi, M.; Abu-Asab, M. S.; Yager, J. A.; Uetrecht, J. P. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 2003, 16, 1078-1089.
41. (b) Shenton, J. M.; Popovic, M.; Chen, J.; Masson, M. J.; Uetrecht, J. P. Evidence of an immune-mediated mechanism for an idiosyncratic nevaripine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. 2005, 18, 1799-1813.
42. Nicoll-Griffith, D. A.; Chauret, N.; Yergey, J. A.; Trimble, L. A.; Favreau, L.; Zamboni, R.; Grossman, S. J.; Drey, J.; Herold, E. Characterization of Verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from b-naphthoflavone- treated rodents (P-450-1A1). Drug Metab. Dispos. 1993, 21, 861-867. (Pubitemid 23298453)
43. Brideau, C.; Kargman, S.; Liu, S.; Dallob, A. L.; Ehrich, E. W.; Roger, I. W.; Chan, C. C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflammation Res. 1996, 45, 68-74.
44. Ferguson, A. D.; McKeever, B. M.; Xu, S.; Wisniewski, D.; Miller, D. K.; Yamin, T.-T.; Spencer, R. H.; Chu, L.; Ujjainwalla, F.; Cunningham, B. R.; Evans, J. F.; Becker, J. W. Science 2007, 317, 510-512.
45. Perrin, D. D. Dissociation Constants of Organic Bases in Aqueous Solutions; IUPAC: Oxford U.K., 1965.
46. Hutchinson, J. H.; Halczenko, W.; Brashear, K. M.; Breslin, M. J.; Coleman, P. J.; Duong, L. T.; Fernandez-Metzler, C.; Gentile, M. A.; Fisher, J. E.; Hartman, G. D.; Huff, J. R.; Kimmel, D. B.; Leu, C.-T.; Meissner, R. S.; Merkle, K.; Nagy, R.; Pennypacker, B.; Perkins, J. J.; Prueksaritanont, T.; Rodan, G. A.; Vargar, S.; Wesolowski, G. A.; Zartman, A. E.; Rodan, S. B.; Duggan, M. E. Nonpeptide αvβ3 antagonists. 8. In vitro and in vivo evaluation of a potent αvβ3 antagonist for the prevention and treatment of osteoporosis. J. Med. Chem. 2003, 46, 4790-4798.
47. Orbach, R. S.; Walsky, R. L.; Venkatakrishnan, K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35, 246-255. (Pubitemid 46148737)
48. Koudriakova, T.; Iatsimirskaia, E.; Utikin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. Metabolism of the human immunodeficiency virus protease inhibitors indanvir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos. 1998, 26, 552-561. (Pubitemid 28498361)
49. Briner, P. H.; Fyfe, M. C. T.; Martin, P.; Murray, P. J.; Naud, F.; Procter, M. J. Practical synthesis of 2-amino-5-fluorothiazole hydrochloride. Org. Process Res. Dev. 2006, 10, 346-348.
50. (a) Henderson, W. R.; Chiang, G. K. S.; Tien, Y.-T.; Chi, E. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med. 2006, 173, 718-728.
51. (b) Henderson, W. R.; Lewis, D. B.; Albert, R. K.; Zhang, Y.; Lamm, W. J. E.; Chiang, G. K. S.; Jones, F.; Eriksen, P.; Tien, Y.-T.; Jonas, M.; Chi, E. Y. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J. Exp. Med. 1996, 184, 1483-1494.
52. (c) Libertine, L., Hutchings, A., Maziarz, A., Cairns, C., LaRosa, G., Newman, W., Kumar, A. A Role for the 5LO Pathway in Allergen- Induced Airway Infiltration of Neutrophils and Eosinophils in a Murine Model of Asthma. Presented at the Annual Meeting of the American College of Allergy, Asthma and Immunology, 2006.